Article info
PDFResearch Article
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma
- ↵a daniel.geynisman{at}uchospitals.edu
- ↵b yzha1{at}bsd.uchicago.edu
- ↵c rangeshk{at}uchicago.edu
- ↵d Mebea.Aklilu{at}advocatehealth.com
- ↵e dcatenac{at}medicine.bsd.uchicago.edu
- ↵f bpolite{at}medicine.bsd.uchicago.edu
- ↵g Cara.Rosenbaum{at}uchospitals.edu
- ↵h Azadeh.Namakydoust{at}uchospitals.edu
- ↵i tkarrison{at}health.bsd.uchicago.edu
- ↵j tgajewsk{at}medicine.bsd.uchicago.edu
- ↵k hkindler{at}medicine.bsd.uchicago.edu
Citation
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma
Publication history
- Received February 26, 2013
- Accepted April 15, 2013
- First published June 27, 2013.
Online issue publication
June 10, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s). 2013